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Objective: Discontinuation of antiepileptic drugs (AEDs) in seizure- free patients is 
an important goal because of possible long- term side effects and the social stigma 
burden of epilepsy. The purpose of this work was to assess seizure recurrence risk 
after suspension of AEDs, to evaluate predictors for recurrence, and to investigate 
the recovery of seizure control after relapse. In addition, the accuracy of a previously 
published prediction model of seizure recurrence risk was estimated.
Methods: Seizure- free patients with epilepsy who had discontinued AEDs were ret-
rospectively enrolled. The frequency of seizure relapses after AED withdrawal as 
well as prognosis after recurrence were assessed and the predictive role of baseline 
clinical- demographic variables was evaluated. The aforementioned prediction model 
was also validated and its accuracy assessed at different seizure- relapse probability 
levels.
Results: The enrolled patients (n = 133) had been followed for a median of 3 years 
(range 0.8– 33 years) after AED discontinuation; 60 (45%) of them relapsed. Previous 
febrile seizures in childhood (hazard ratio [HR] 3.927; 95% confidence interval [CI] 
1.403– 10.988), a seizure- free period on therapy of less than 2 years (HR 2.313; 95% 
CI 1.193– 4.486), and persistent motor deficits (HR  4.568; 95% CI 1.412– 14.772) 
were the clinical features associated with relapse risk in univariate analysis. Among 
these variables, only a seizure- free period on therapy of less than 2 years was as-
sociated with seizure recurrence in multivariate analysis (HR 2.365; 95% CI 1.178– 
4.7444). Pharmacological control of epilepsy was restored in 82.4% of the patients 
who relapsed. In this population, the aforementioned prediction model showed an 
unsatisfactory accuracy.
Significance: A period of freedom from seizure on therapy of less than 2 years was 
the main predictor of seizure recurrence. The accuracy of the previously described 
prediction tool was low in this cohort, thus suggesting its cautious use in real- world 
clinical practice.
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1 |  INTRODUCTION
Antiepileptic drugs (AEDs) are effective in about 65%– 85% 
of patients with epilepsy.1,2 One of the main open questions in 
this field is treatment duration after achieving seizure remis-
sion. In fact, the discontinuation of AEDs in seizure- free pa-
tients remains a desirable clinical achievement, since at least 
one side effect of AEDs is observed in up to 88% of cases (eg, 
behavioral and cognitive effects, teratogenic risk, and drug 
interactions).1– 6 In addition, interrupting AEDs can lead to a 
significant improvement in the quality of life of patients with 
epilepsy, with important psychosocial implications, since pa-
tients perceive themselves not only as free from drugs and 
seizures but also without any social stigma.3,7– 11
However, AED discontinuation is a demanding clini-
cal task due to its possible detrimental consequences in the 
case of seizure recurrence (eg, injuries, loss of self- esteem, 
unemployment, loss of the driving license, and so on).12 To 
properly tailor this decision, many potential risk factors of 
recurrence have been reported in the literature, but evidence 
supporting them is still weak.13 In particular, only two ran-
domized controlled trials (RCTs) comparing seizure recur-
rence risk between AED discontinuation and maintenance 
have been published, showing opposite results. The first one, 
a British Medical Research Council- based multicenter RCT, 
showed a seizure recurrence risk in the AED discontinuation 
group higher than in continuers, whereas the second one, a 
Norway- based multicenter double- blinded RCT, did not.14,15
Several multivariate prediction models have also been pro-
posed in the literature but these tools have shown limitations 
that make them poorly applicable as they are based on too 
selected populations.13,16– 19 In addition, the available models 
are hardly comparable, in terms of inclusion criteria.13,16– 19 
In 2017, starting from an individual participant data meta- 
analysis based on the raw data of 10 studies (including a total 
of 1769 patients), Lamberink et al. developed a predictive 
model estimating seizure recurrence risk at 2 and 5 years after 
AED withdrawal (from now on called Lamberink's prediction 
model, LPM).2 This model is believed to be well applicable 
in daily clinical practice as it is based on a heterogeneous co-
hort, close to real- life experience.2,20,21 The accuracy of LPM 
was internally cross- validated but also externally by only two 
studies, both in Chinese populations.2,20,21
In the present study, seizure recurrence after AED discon-
tinuation was retrospectively evaluated in an Italian patient 
cohort evaluating several risk factors correlated with seizure 
relapse. Moreover, clinical course after seizure recurrence 
was also estimated by assessing the number of patients re-
covering pharmacological control and the clinical variable 
associated with this achievement. Finally in this cohort, a ret-
rospective validation of the accuracy of LPM was performed.
The LPM for risk of seizure recurrence at 2 and 5 years 
provides an individual recurrence probability, without defin-
ing a threshold value dividing patients as high or low risk of 
recurrence, making it difficult to apply in clinical practice.2 
For this reason, the purpose of this work was also to identify 
a practical threshold probability.
2 |  METHODS
2.1 | Study design
This work is an observational retro- prospective cohort study 
conducted at the Epilepsy Regional Referral Center (ERRC) 
of the Neurology 2 Department of Careggi University 
Hospital (Florence, Italy), a third- level medical center. The 
study respects the Declaration of Helsinki and has been ap-
proved by the hospital ethics committee (code:14385_oss). 
K E Y W O R D S
AED withdrawal, anti- seizure medications, epilepsy
Key Points
• Discontinuation of antiepileptic drugs (AEDs) in 
seizure- free patients is an important goal because 
of side effects and the social stigma burden of 
epilepsy.
• Seizure relapses and possible predictors of recur-
rence were evaluated in 133 patients followed for 
a median of 3 years after AED withdrawal.
• Regain of control after seizure relapse and the 
accuracy of a prediction model of seizure recur-
rence risk published by Lamberink et al. were also 
estimated.
• A period of freedom from seizure on therapy of 
less than 2 years was the main predictor of seizure 
recurrence.
• About 82% of patients regained seizure control 
after relapse but no predictor of the recovery could 
be identified.
• The accuracy of the Lamberink prediction model 
was low in this cohort suggesting its cautious use 
in real- world clinical practice
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Written informed consent for data gathering was obtained 
from each patient.
2.2 | Patients
Patients who fulfilled the diagnostic criteria for epilepsy,22 
followed between January, 1983 and November, 2018 at the 
ERRC, were included according to the following criteria: 
seizure- free subjects who interrupted AEDs from the age of 
at least 16 and were thereafter followed for a minimum of 
2 years or until seizure recurrence. Exclusion criteria were 
incomplete clinical records, a follow- up shorter than 2 years 
without a recurrence, AED discontinuation without being 
seizure- free, seizures not fulfilling the diagnostic criteria for 
epilepsy (eg, acute symptomatic seizures occurring within 1 
week of a brain insult23), interruption of prophylactic AEDs 
(eg, patients undergoing neurosurgery who had never expe-
rienced seizures), and AED withdrawal performed after sur-
gery for epilepsy. Clinical records were used to gather all 
the necessary clinical demographic variables. The data were 
collected retrospectively if patients had discontinued AEDs 
before 2010 and partially prospectively until January 1, 2020, 
if they had interrupted AEDs thereafter. In order to collect 
follow- up data also of the patients who missed on- site visits, 
the clinical status of these patients (ie, seizure freedom in the 
years after the beginning of AEDs withdrawal) was inves-
tigated by phone calls. To analyze seizure- free intervals on 
therapy before AED withdrawal and duration of AED taper-
ing as possible risk factors of seizure recurrence, these pa-
rameters were not part of the inclusion criteria.
2.3 | Clinical- demographic 
characteristics analyzed
The following clinical- demographic characteristics were 
recorded: sex, age at seizure onset (stratified according to 
Lamberink et al.2), duration of epilepsy (from the first to 
the last seizure), family history of epilepsy, neonatal sei-
zures (until the first month of life), febrile seizures in child-
hood, number of seizures before AED discontinuation (<10 
or ≥10),2 duration of the seizure- free period on therapy 
(from the last seizure attack to AED withdrawal; variable 
was recorded both categorized according to Wang et al.24 
and continuous), number of discontinued drugs, seizure 
type (focal/generalized), etiology of epilepsy (structural, 
assessed by magnetic resonance imaging [MRI]; genetic; 
unknown), diagnosis of a self- limiting epilepsy syndrome 
(eg, absence epilepsy, benign epilepsy with centrotemporal 
spikes, Panayiotopoulos syndrome), developmental delay 
(assessed only by clinical judgment and history of need for 
specialized schooling, as in 3/10 of the papers included in the 
meta- analysis of Lamberink et al.2), electroencephalography 
(EEG) epileptiform abnormalities before discontinuation, 
age at last seizure, age at AED withdrawal, plasma levels 
of AEDs at the beginning of withdrawal (within, below, or 
above therapeutic range), persistent motor deficits, psychiat-
ric disorders for which the patient assumed a specific drug, 
failure of previous AED discontinuations, duration of AED 
tapering (0– 3 months; 4– 12 months; more than 1 year), epi-
leptiform abnormalities on EEG during or at the end of AED 
withdrawal, epileptic encephalopathy, and presence of juve-
nile myoclonic epilepsy.
For LPM validation in this patient cohort, the 2- and 5- 
year seizure recurrence probability for each patient was es-
timated using the web- based tool developed by the authors 
(http://epile psypr edict ionto ols.info).2
As for the time to seizure recurrence, this variable was 
evaluated starting from the beginning of AED tapering, 
since seizure recurrence risk can increase starting from this 
time.25 Therefore, as in previous studies, the relapses that oc-
curred during the tapering period were also included in the 
analyis.14,25– 28
Seizures were accepted when validated by an EEG re-
corded during the event, or when they were reported to the 
neurologist with suggestive features by a witness (clinician/
relative/friend of the patient), or self- reported by the patients 
themselves.
In the patients who experienced seizure recurrence, the 
recovery of pharmacological control of epilepsy after the 
recurrence and time to new seizure control, defined as the 
presence at the last follow- up of a seizure- free interval of 
at least 1 year,29,30 were also evaluated. Finally, the type of 
the new therapy started again after recurrence was also as-
sessed (same AEDs as before withdrawal at same dose/same 
AEDs at a lower dose/same AEDs at a higher dose/different 
monotherapy/polytherapy).
2.4 | Statistics
Statistical analyses were carried out using SPSS version 12 
and R (The R Project for Statistical Computing, Vienna, 
Austria) version 4.0.3 packages. All statistical tests were two- 
tailed and p < 0.05 was considered statistically significant.
Frequencies were used for categorical variables, whereas 
average/standard deviation (SD) or median/range were used 
for continuous variables according to their distribution (nor-
mal or not, respectively, according to the Shapiro- Wilk test).
Statistical analysis of the selected outcomes (seizure re-
currence and recovery of pharmacological control after re-
currence) was based on the evaluation of the time to the first 
event by the Kaplan- Meier method.
To evaluate the baseline clinical- demographic vari-
ables associated with increased risk of seizure recurrence, 
2162 |   CONTENTO ET al.
univariate and multivariate analyses with the Cox regression 
model were performed, calculating the hazard ratios (HRs) 
with their 95% confidence intervals (CIs). For multivariate 
analysis, only the variables that resulted significant at the 
univariate were included. Univariate and multivariate anal-
yses with the Cox regression model were also performed to 
evaluate the variables associated with the chance to recover 
a new pharmacological seizure control in the patients who 
experienced seizure relapse.
Considering that the authors of LPM did not define a 
threshold value that divides patients as high or low risk of 
seizure recurrence, a specifically devised algorithm was de-
veloped to assess the accuracy of LPM in this patient cohort 
that permits its evaluation at each possible recurrence risk 
threshold probability value. Each possible threshold prob-
ability value was identified in the sequence of increase of 
2% between 0 and 100% (51 recurrence risk threshold prob-
ability values, extremes included). The extreme values of 
LPM are <10% and >90%. No patient in this study showed 
a recurrence risk probability value >90% but for those with 
a probability <10%, the central value of that interval was as-
signed (ie, 5%). This algorithm was implemented with the R 
software and also produced the CIs at 95% both for sensitiv-
ity and specificity curves through the bootstrap technique. 
The bootstrap is a statistical resampling method used to ob-
tain an estimation of the sampling distribution of almost any 
statistics. In this analysis, empirical CIs were generated by 
extracting 10,000 subsamples of 80 patients for each pos-
sible threshold value and by calculating the 2.5 and 97.5 
percentiles from the sensitivity and specificity subsample 
distribution (with a cohort of 133 patients, the universe of 
all the possible subsamples of 80 patients has a cardinality 
of 4.861139e+37).
3 |  RESULTS
3.1 | Seizure recurrence risk
Of the 4154 patients diagnosed with epilepsy between January 
1, 1983 and November 30, 2018, a total of 205 had discontin-
ued AEDs. After applying the selection criteria, a final cohort 
of 133 patients was extracted. For 12 of the 72 excluded pa-
tients, exclusion occurred because they were lost at follow-
 up before the end of the second year after AED withdrawal, 
or before any eventual seizure recurrence, although in each 
case phone contacts were repeatedly attempted (Figure 1).
The 133 patients included were followed for at least 
2 years or until any recurrence, for a median of 3 years (0.8– 
33 years) after the beginning of AED withdrawal. The main 
baseline characteristics of this cohort are reported in Table 1. 
The AEDs most used were levetiracetam (30.1% of patients), 
carbamazepine (24.8%), valproic acid (13.5%), lamotrigine 
(11.3%), and phenobarbital (11.3%).
Sixty patients (45%) relapsed after AED discontinu-
ation; 73 (55%) did not. Nineteen of the 73 patients (26%) 
who did not relapse were followed for at least 5 years and, 
including the duration of their seizure- free interval on ther-
apy, 13 of them (68.4%) had been seizure- free for 10 years, 
without AEDs for at least the last 5 years. Thus according to 
International League Against Epilepsy (ILAE) criteria, these 
patients can be considered to have resolved epilepsy.22
For the 60 patients (45%) who relapsed after AED dis-
continuation, the cumulative risk of seizure recurrence at 6 
months was 13.5%, at 1 year 30.8%, at 2 years 39.1%, at 3 
years 41.4%, and at 5 years 44.7% (Figure 2A). The median 
time to seizure recurrence from the beginning of AED taper-
ing was 304 days (30– 5840 days). Of the 60 patients who had 
F I G U R E  1  Patients enrolled in 
the study. Two hundred five patients 
discontinued antiepileptic drugs (AEDs) of 
the 4154 patients diagnosed with epilepsy 
between January 1, 1983 and November 30, 
2018, at Epilepsy Regional Referral Center 
(ERCC) of the Neurology 2 Department 
of Careggi University Hospital (Florence, 
Italy). After applying the inclusion criteria, a 
final cohort of 133 patients was selected.
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T A B L E  1  Clinical- demographic features and potential risk factors of seizure recurrence after AED discontinuation evaluated by Cox 
regression model
Variables N = 133
Univariate for seizure recurrence
HR (95% CI) p- value
Sex (%)
F 63 (47.4%) 1.110 (0.665– 1.852) 0.689
M 70 (52.6%) Reference value
Family history of epilepsy (%) 11 (8.3%) 1.012 (0.404– 2.536) 0.980
History of neonatal seizures (%) 0 - - 
History of febrile seizures in childhood (%) 4 (3%) 3.927 (1.403– 10.988) 0.009*
Age at seizure onset (%)a 
Childhood (0– 10 years) 12 (9%) Reference value
Adolescent (11– 17 years) 20 (15%) 1.088 (0.361– 3.280) 0.881
Adult age (≥18 years) 101 (75.9%) 1.179 (0.464– 2.996) 0.729
No. of seizures before AED withdrawal
0– 9 110 (82.7%) Reference value
10 or more 23 (17.3%) 0.485 (0.209– 1.130) 0.093
Median duration of epilepsy in months (range) 6 (0– 480) 0.998 (0.995– 1.002) 0.378
Median age at last seizure (range) 34 (9– 80) 0.997 (0.984– 1.010) 0.647
Seizure type
Generalized 19 (14.3%) Reference value
Focal 114 (85.7%) 0.864 (0.434– 1.722) 0.678
Etiology of epilepsy
Structural 75 (56.4%) 1.023 (0.613– 1.708) 0.930
Genetic 0 – 
Unknown 58 (43.6%) Reference value
Self- limiting epilepsy syndrome 2 (1.5%) 21.230 (0.010– 43698.239) 0.433
Juvenile myoclonic epilepsy 6 (4.5%) 0.720 (0.175– 2.953) 0.648
Epileptic encephalopathy 1 (0.8%) 3.936 (0.537– 28.864) 0.178
Development delay 5 (3.8%) 1.976 (0.616– 6.337) 0.252
Persistent motor deficits 3 (2.3%) 4.568 (1.412– 14.772) 0.011**
Psychiatric abnormalities 26 (19.5%) 0.786 (0.398– 1.553) 0.489
Seizure- free period on therapy (months)b 
0– 23 20 (15%) 2.313 (1.193– 4.486) 0.013***
24– 35 16 (12%) 1.479 (0.665– 3.291) 0.338
36– 47 21 (15.8%) 0.834 (0.375– 1.855) 0.656
48– 59 15 (11.3%) 0.913 (0.349– 2.389) 0.853
60 or more 61 (45.9%) Reference value
Median age at withdrawal (range) 43 (16– 84) 0.993 (0.980– 1.007) 0.313
EEG before AEDs withdrawal
Normal 72 (54.1%) Reference value
Epileptiform abnormality 2 (1.5%) 1.302 (0.173– 9.789) 0.797
Failure of previous AEDs discontinuations 12 (9%) 0.843 (0.337– 2.109) 0.714
Number of AEDs discontinued
One 130 (97.7%) Reference value
Two 3 (2.3%) 2.346 (0.571– 9.641) 0.237
(Continues)
2164 |   CONTENTO ET al.
a seizure recurrence, it occurred within the first year from the 
beginning of tapering in 68.3% of them, and within 2 years 
in 86.7% of them. Only 13.3% of these 60 patients had recur-
rence after 2 years and only 6.7% after 5 years.
Univariate analysis showed that significant risk factors 
associated with seizure relapse were: the presence of febrile 
seizures in childhood (HR  3.927; 95% CI 1.403−10.988), 
duration of the seizure- free period on therapy shorter than 
2 years (HR 2.313; 95% CI 1.193– 4.486), and presence of 
persistent motor deficits (HR 4.568; 95% CI 1.412 −14.772) 
(Table 1). Multivariate analysis revealed that among these 
factors, only the duration of the seizure- free period on ther-
apy shorter than 2 years holds a statistically significant asso-
ciation with seizure relapse (HR 2.365; 95% CI 1.178– 4.744) 
(Figure 2B). Subsequently, a post hoc analysis was carried 
out to better define the effect on seizure recurrence risk of a 
seizure- free period on therapy of 2 years or longer but shorter 
than 3 years. Thus only three possible values were assigned to 
the variable “duration of the seizure- free period on therapy” 
(36– 47 months, 48– 59 months, and 60 or more months) and 
a log- rank test was performed among the three curves to eval-
uate the difference between the expected and observed re-
currences. As shown in Figure 2C, also a seizure- free period 
on therapy of 2 years or longer but shorter than 3 years led 
to an increased seizure recurrence risk with more observed 
recurrences than expected (not significant). Instead, having 
a seizure- free period on therapy of 3 years or longer did not 
seem to further reduce seizure recurrence risk (Figure 2C).
3.2 | Probability of gaining a new seizure 
control after recurrence
Among the 60 patients who relapsed, 59 agreed to start 
AEDs again. Of these, 51 patients were followed for at least 
1 year after the relapse (median 5 years; range 1– 33). The 
main clinical features of this cohort are reported in Table 2. 
During this period, of these 51 patients, 42 regained seizure 
control (82.4%), 5 did not (10%), and 4 (7.8%) developed 
drug- resistant epilepsy. Out the 42 patients who regained 
seizure control, 35 (83.3%) did it within the first year from 
recurrence, 36 (85.7%) within the first 2 years, 39 (92.9%) 
within the first 3 years, and 40 (95.2%) within the first 4 
years. The last two patients gained a new control after 9 
and 24 years, respectively (Figure 2D). The majority of pa-
tients gained new seizure control with monotherapy (41 of 
42 patients, 97.6%); in particular, 26 with the same AEDs 
as before the discontinuation at a higher dose (6 patients ), 
at the same dose (13 patients), or a lower dose (7 patients). 
From univariate analysis, no clinical- demographic features 
resulted as associated with the gain of new seizure control 
(Table 2).
Variables N = 133
Univariate for seizure recurrence
HR (95% CI) p- value
Plasma levels of AEDs at the beginning of withdrawal
Below range 21 (15.8%) 1.226 (0.534– 2.815) 0.631
Within range 66 (49.6%) Reference value
Above range 0 – 
Duration of AEDs tapering
0– 3 months 41 (30.8%) 5.912 (0.794– 44.044) 0.083
4– 12 months 69 (51.9%) 3.678 (0.498– 27.144) 0.202
More than 1 year 1 (0.8%) Reference value
EEG during/at the end of AEDs withdrawal
Normal 94 (70.7%) Reference value
Epileptiform abnormality 9 (6.8%) 2.059 (0.869– 4.879) 0.101
Missing data for the variable “EEG before AED withdrawal”: 59 (44.4%).
Missing data for the variable “Plasma levels of AEDs at the beginning of withdrawal”: 46 (34.6%).
Missing data for the variable “Duration of AED tapering”: 14 (10.5%).
Missing data for the variable “EEG during/at the end of AED withdrawal”: 30 (22.6%).
AED, antiepileptic drug; CI, confidence interval; EEG, electroencephalography; HR, hazard ratio.
aThe subdivision of age groups is the same as in Lamberink et al2
bThe subdivision of seizure- free period on therapy is the same as in Wang et al21
*Multivariate analysis: HR 2.865 (95% CI 0.709– 11.567) p = 0.139.; **Multivariate analysis: HR 2.842 (95% CI 0.566– 14.265) p = 0.204.; ***Multivariate analysis: 
0– 23 months: HR 2.600 (95% CI 1.318– 5.129) p = 0.006; 24– 35 months: HR 1.694 (95% CI 0.750– 3.827) p = 0.205; 36– 47 months: HR 0.905 (95% CI 0.401– 2.043) 
p = 0.811; 48– 59 months: HR 1.041 (95% CI 0.393– 2.758) p = 0.935.
T A B L E  1  (Continued)
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3.3 | Retrospective validation of LPM in 
our cohort
The accuracy of the LPM in our cohort was analyzed 
via our algorithm at each possible identified threshold 
probability value, showing that the model has an unsat-
isfactory accuracy for the risk both at 2 and 5 years. As 
shown in Figure 3, applying, for instance, a threshold 
probability value of 0.5 at 2 years, sensitivity would be 
40% and specificity 60%, and at 5 years sensitivity would 
F I G U R E  2  A, Time to first seizure recurrence from the beginning of antiepileptic drug (AED) tapering is displayed according to the 
Kaplan- Meier method. On the x- axis, time 0 represents the beginning of AED tapering up to the discontinuation. The number of patients at risk 
at each time is reported under the x- axis. B, Multivariate analysis with the Cox regression model is presented, stratified according to the duration 
of the seizure- free period on therapy. Each curve represents the whole population and it is weighted in the same way for the other two factors 
implemented in the multivariate analysis (febrile seizures in childhood and persistent motor deficit; both are fixed to their average values). The 
only element differentiating the curves are the five different values that were assigned to the variable “seizure- free period on therapy.” A seizure- 
free period on therapy shorter than 2 years was significantly associated with recurrence risk (hazard ratio [HR] 2.365; 95% confidence interval 
[CI] 1.178– 4.7444). It is notable that the strata encompassing the longest seizure- free periods (36– 47 months, 48– 59 months, and 60 or more 
months) substantially overlap: Having a seizure- free period on therapy longer than 3 years does not seem to lead to any further reduction in seizure 
recurrence risk (not significant). C, Post hoc analysis of the results represented in 2B. The curves displayed are the graphical representation of 
multivariate analysis with the Cox regression model where the possible values assigned to the variable “duration of the seizure- free period on 
therapy” are 0– 23 months, 24– 35, and 36 or more months. A period shorter than 2 years is still the only significant seizure recurrence risk factor 
but, as shown in the table below the graph, also a period of 2 years or longer but shorter than 3 years leads to an increased seizure recurrence risk 
with more observed recurrences than expected (not significant). D, Time to restore seizure pharmacological control after relapse, displayed using 
the Kaplan- Meier method. On the x- axis, 0 represents the time of seizure relapse after AED discontinuation. The patients at risk at each time are 
reported under the curve.
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T A B L E  2  Clinical- demographic features of the 51 patients who restarted AEDs after seizure recurrence and were followed for at least one 
year. Factors associated with the achievement of new pharmacological control evaluated by the Cox regression model are also reported.
Variables N = 51
Univariate for new seizure control
HR (95% CI) p- value
Sex (%)
F 27 (52.9%) 1.048 (0.567– 1.937) 0.881
M 24 (47.1%) Reference value
Family history of epilepsy (%) 4 (7.8%) 0.405 (0.95– 1.733) 0.223
History of neonatal seizures (%) 0 - 
History of febrile seizures in childhood (%) 3 (5.9%) 1.5 (0.459– 4.898) 0.502
Age at seizure onset (%)a 
Childhood (0– 10 years) 5 (9.8%) Reference value
Adolescent (11– 17 years) 7 (13.7%) 0.991 (0.279– 3.522) 0.989
Adult age (≥18 years) 39 (76.5%) 1.037 (0.365– 2.951) 0.945
No. of seizures before AED withdrawal
0– 9 45 (88.2%) Reference value
10 or more 6 (11.8%) 0.736 (0.260– 2.080) 0.563
Median duration of epilepsy in months (range) 6 (0– 480) 0.999 (0.996– 1.003) 0.651
Median age at last seizure (range) 31 (12– 80) 0.999 (0.983– 1.015) 0.905
Seizure type
Generalized 10 (19.6%) Reference value
Focal 41 (80.4%) 0.807 (0.384– 1.697) 0.573
Etiology of epilepsy
Structural 29 (56.9%) 0.767 (0.412– 1.427) 0.402
Genetic 0 – 
Unknown 22 (43.1%) Reference value
Self- limiting epilepsy syndrome 0 – 
Juvenile myoclonic epilepsy 2 (3.9%) 1.198 (0.288– 4.985) 0.804
Epileptic encephalopathy 1 (2%) 1.471 (0.201– 10.743) 0.704
Development delay 3 (5.9%) 0.715 (0.171– 2.987) 0.645
Persistent motor deficits 2 (3.9%) 0.044 (0– 21.567) 0.323
Psychiatric abnormalities 8 (15.7%) 0.717 (0.281– 1.829) 0.486
Seizure- free period on therapy (months)b 
0– 23 13 (25.5%) 1.042 (0.472– 2.299) 0.918
24– 35 7 (13.7%) 1.074 (0.421– 2.735) 0.882
36– 47 6 (11.8%) 1.036 (0.382– 2.813) 0.944
48– 59 5 (9.8%) 0.693 (0.202– 2.377) 0.560
60 or more 20 (39.2%) Reference value
Median age at withdrawal (range) 39 (16– 81) 0.999 (0.982– 1.016) 0.885
EEG before AED withdrawal
Normal 25 (49%) Reference value
Epileptiform abnormality 1 (2%) 1.471 (0.196– 11.050) 0.708
Failure of previous AED discontinuations 4 (7.8%) 0.867 (0.266– 2.822) 0.812
Number of AEDs discontinued
One 49 (96%) Reference value
Two 2 (4%) 0.688 (0.094– 5.024) 0.712
(Continues)
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be 60% and specificity 40%. For the prediction risk at 2 
years, using a sensitivity level of 75%, at the correspond-
ing threshold value we would have a specificity level of 
40%: in 60% of patients, we would predict a false sei-
zure recurrence. If instead, we set a higher specificity, 
for instance at 80%, the sensitivity would be 20% at the 
corresponding threshold value, meaning that in 80% of pa-
tients a seizure recurrence would not be predicted. With a 
sensitivity of 90%, a specificity of 10% would have been 
observed, meaning that a false seizure recurrence would 
have been predicted in 90% of patients (Figure 3A). The 
same unsatisfactory risk predictions could be made with 
reference to 5 years (Figure 3B).
4 |  DISCUSSION
The current work presents long- term follow- up data of an 
Italian cohort of adult patients with epilepsy who discontin-
ued their AEDs. The frequency of relapses is consistent with 
previous studies where the range of seizure recurrence was 
12%- 67%.2,12,13,20,21,30,31 In particular, in two other external 
validation papers on LPM, 59%20 and 44%,21 respectively, of 
patients relapsed.
The risk factors evaluated were the same reported in the 
previous papers, and definitions of these variables are con-
sistent with them.2,13,17,30 However, to broadly evaluate the 
potential effect on seizure recurrence risk, patients with 
Variables N = 51
Univariate for new seizure control
HR (95% CI) p- value
Plasma levels of AEDs at the beginning of withdrawal
Below range 7 (13.7%) 1.021 (0.383– 2.723) 0.967
Within range 14 (27.5%) Reference value
Above range 0
Duration of AED tapering
0– 3 months 18 (35.3%) 1.051 (0.519– 2.131) 0.890
4– 12 months 21 (41.2%) Reference value
More than 1 year 0
EEG during/at the end of AED withdrawal
Normal 34 (66.7%) Reference value
Epileptiform abnormality 5 (9.8%) 1.381 (0.529– 3.610) 0.510
Seizure recurrence
During AED tapering 9 (17.6%) Reference value
At the end of AED withdrawal 42 (82.4%) 1.039 (0.460– 2.346) 0.926
Median time to seizure recurrence (days, range) 304 (30– 5840) 1 (1– 1) 0.762
Median duration of the seizure- free interval after restarting a 
treatment (years, range)
4 (1– 33)
Therapeutic modifications after recurrence
Same AEDs lower dose 7 (13.7%) Reference value
Same AEDs same dose 13 (25.5%) 1.064 0.895
Same AEDs higher dose 8 (15.7%) 0.596 0.358
Different monotherapy 17 (33.3%) 0.737 0.513
Polytherapy 5 (9.8%) 0.149 0.077
No therapy 1 (2%) 0 (0– 0) 0.980
Missing data for the variable “EEG before AED withdrawal”: 25 (49%).
Missing data for the variable “Plasma levels of AEDs at the beginning of withdrawal”: 30 (58.9%).
Missing data for the variable “Duration of AED tapering”: 12 (23.5%).
Missing data for the variable “EEG during/at the end of AED withdrawal”: 12 (23.5%).
AED, antiepileptic drug; CI, confidence interval; EEG, electroencephalography; HR, hazard ratio.
aThe subdivision of age groups is the same as the paper of Lamberink et al2
bThe subdivision of seizure- free period on therapy is the same as the paper of Wang et al21
T A B L E  2  (Continued)
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different tapering times and different seizure- free periods on 
therapy were included.
In this work, a seizure- free period on therapy of less 
than 2 years is an independent predictor of increased re-
currence risk. This result is coherent with some previous 
reports,1,14,27 whereas others showed either different cut- 
offs (5 or 3 years) or progressive reduction of risk without 
giving any definite cut- off value.2,24,31 Therefore, until more 
evidence is gathered, it seems important that future studies 
include patients with different duration of seizure- free pe-
riod on therapy.
The results about the disease's natural history after seizure 
recurrence are encouraging and they should reassure clini-
cians facing decisions regarding AED withdrawal. The per-
centage of patients who obtained a new control of epilepsy 
after recurrence (82.4%) is consistent with other published 
series (64– 91%).2,12 Ultimately, only 7.8% of our patients 
developed drug- resistant epilepsy (other groups have shown 
results ranging from 7 to 23%).2,12 Unfortunately, no predic-
tor of the recovery of seizure control could be identified, and 
there was not sufficient statistical power to analyze the drug- 
resistant cohort from the sample size of the study. Very few 
studies have addressed the issue of epilepsy prognosis after 
recurrence following AED discontinuation, and there is no 
evidence that either discontinuation itself or pharmacolog-
ical treatment of a recurrence are predictors of seizure out-
come.12,29,32– 35 Other works identified the following negative 
predictive factors regarding new control: a structural etiology 
with or without mental delay and a long duration of epilepsy 
in children, the diagnosis of juvenile myoclonic epilepsy in 
adolescence, and epilepsy with focal motor seizure with im-
paired awareness in adults.12,33
The unsatisfactory accuracy of the LPM in the present co-
hort is not consistent with the internal validation performed 
by Lamberink et al.,2 and only in part consistent with the two 
other external validations of the method published in the past, 
by Lin et al. and Chu et al.20,21 This could be due to the dif-
ferent populations included in the analysis or to the sample 
size. In the present study, the proportion of adults is higher 
than in the LPM2 as for age both at AED withdrawal (a me-
dian of 43 years in this study vs 15 years in LPM work2) and 
at seizure onset (75.9% of the patients in the present work 
developed epilepsy at adult age vs 17% of patients in the 
LPM paper2). The different ages at seizure onset may have 
determined different frequencies of specific epilepsy syn-
dromes, for example, self- limiting syndromes (just 1.5% in 
the present study vs 19% in Lamberink et al.2), which are 
usually associated with a favorable prognosis. Despite that, 
the frequency of relapses in this work is consistent with that 
of the LPM study2 (45% and 46%, respectively). Moreover, 
in a population similar to that of the original meta- analysis, 
the accuracy of LPM was confirmed only as for the risk of 
seizure recurrence at 5 years.21 Then, the size of the present 
cohort is similar to the above- mentioned external validation 
papers and it should be remarked that the LPM is supposed to 
be widely applicable in clinical practice.2,20,21
A major obstacle to the practical implementation of LPM 
is represented by the lack of a single threshold probability 
value that separates high- risk from low- risk patients. Lin 
et al. tried to overcome this issue by a decision curve analy-
sis: This method, unfortunately, did not offer a specific cut- 
off but it revealed that the model's usefulness resides in a 
specific probability range.20 On the contrary, Chu et al. pro-
posed a cut- off by calculating the largest Youden index on 
receiver- operating characteristic (ROC) curves: at 2 years 
this value was 47% (with a sensitivity of 0.758 and a spec-
ificity of 0.410), whereas at 5 years it was 77% (sensitivity 
of 0.358 and a specificity of 0.979).21 These findings do not 
seem clinically satisfactory (eg, with a cut- off value of 77% 
at 5 years, true seizure recurrence would have not been pre-
dicted in 64.2% of patients).21 Moreover, the Youden index 
is a mathematical way of summarizing the performance of a 
F I G U R E  3  A, Sensitivity and specificity (y- axis) plotted at different probability threshold values generated by the Lamberink prediction model 
(LPM) for seizure recurrence risk at year 2. Dashed curves identify the confidence intervals (CIs). At year 2, under these experimental conditions, 
LPM shows low accuracy. B, Same parameters at year 5. Under these experimental conditions, LPM shows low accuracy also at year 5.
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dichotomous diagnostic test: Its maximum value is often used 
as a detecting criterion of the optimal cut- off point.
Instead, in the present paper, a full evaluation of the ac-
curacy of LPM was performed by assessing its sensitivity 
and specificity for each possible threshold value. In addition, 
thanks to the bootstrap method, we were able to show the 
reliability of our measures with their confidence intervals. 
We aimed to provide clinicians with a complete appraisal of 
LPM, by allowing them to tailor decisions on a single pa-
tient. However, no threshold value was shown to yield suf-
ficient accuracy, indicating that in this patient cohort LPM 
is inadequate. In fact, it generates either an excessive risk of 
recurrence if high specificity is chosen and consequently low 
sensitivity, or an excessively conservative attitude, if the op-
posite values are selected.
The main limit of our study is the retrospective design 
and subsequent risk of recall bias, although it was mitigated 
by verifying the patient referral of seizure recurrence with 
objective records whenever possible (eg, clinical records of 
the emergency department). The long timeframe of the ret-
rospective enrollment might have expanded heterogeneity 
in the cohort because of a modification of the attitude to-
ward AED discontinuation throughout the years. However, 
in this period, the patients had been consistently followed by 
the same neurologists, thus maintaining a standard and uni-
form clinical approach. In addition, recruitment bias cannot 
be excluded. This could be related to the loss of patients be-
fore treatment interruption and, therefore, before inclusion. 
It cannot be excluded that some patients might have discon-
tinued AEDs according to the advice of other neurologists. 
However, we think that if such an event occurred, it should 
have affected the sample size more than having introduced 
a recruitment bias; in this case, no reason other than chance 
can be hypothesized for leaving under treatment the largest 
epilepsy referral center in the metropolitan area. As for the 
sample size of this paper (133 patients), it is similar to the 
two external validations20,21 and large enough to prove a sta-
tistically significant association between a seizure- free pe-
riod on therapy shorter than 2 years and seizure recurrence. 
In addition, according to the high severity of the population 
under treatment in a third- level clinical center— rarely dis-
continuing AEDs— the patient numerosity included should 
be representative.
Large, multicenter, and multiregional studies are nonethe-
less needed to generate conclusive data about the recurrence 
risk after AED withdrawal, and to improve the detection of 
relevant risk factors. As already proposed by others, the poor 
accuracy of the LPM herein observed suggests that it should 
be reviewed and integrated with more informative diagnostic 
tools as covariates, such as neurophysiological markers of the 
epileptogenic network (eg, scalp- recorded high- frequency 
oscillations [HFOs]).36– 40
5 |  ETHICAL PUBLICATION 
STATEMENT
We confirm that we have read the Journal's position on issues 
involved in ethical publication and affirm that this report is 
consistent with those guidelines.
6 CONFLICT OF INTEREST
Luca Massacesi, MD, received fees for participation in the 
advisory board, faculty of teaching courses, or scientific 
consultation from Novartis, Biogen, Roche, Mylan, Merck- 
Serono, and Sanofi- Genzyme. Educational grants were 
also received from Merck- Serono, Teva, Sanofi- Genzyme, 
Biogen, Novartis, Roche, and Mylan. Eleonora Rosati, MD, 
received fees for participation in advisory board or scientific 
consultation from Eisai, GW, Bial, and UCB. The remaining 
authors have no conflicts of interest to disclose.
ORCID
Margherita Contento   https://orcid.
org/0000-0001-8806-6685 
Luca Massacesi   https://orcid.org/0000-0001-5083-372X 
Marco Paganini   https://orcid.org/0000-0002-9603-2378 
REFERENCES
 1. Strozzi I, Nolan SJ, Sperling MR, Wingerchuk DM, Sirven 
J. Early versus late antiepileptic drug withdrawal for peo-
ple with epilepsy in remission. Cochrane Database Syst Rev. 
2015;2015:CD001902.
 2. Lamberink HJ, Otte WM, Geerts AT, Pavlovic M, Ramos- Lizana 
J, Marson AG, et al. Individualised prediction model of seizure re-
currence and long- term outcomes after withdrawal of antiepileptic 
drugs in seizure- free patients: a systematic review and individual 
participant data meta- analysis. Lancet Neurol. 2017;16:523– 31.
 3. Zou X, Hong Z, Chen J, Zhou D. Is antiepileptic drug withdrawal 
status related to quality of life in seizure- free adult patients with 
epilepsy? Epilepsy Behav. 2014;31:129– 35.
 4. Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of 
antiepileptic drugs. Ther Adv Neurol Disord. 2011;4:385– 407.
 5. Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic 
drug effects: toward a clinically and neurobiologically relevant tax-
onomy. Neurology. 2009;72:1223– 9.
 6. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality 
of life of people with epilepsy: a European study. Epilepsia. 
1997;38:353– 62.
 7. Jacoby A, Johnson A, Chadwick D. Psychosocial outcomes 
of antiepileptic drug discontinuation. The Medical Research 
Council antiepileptic drug withdrawal Study Group. Epilepsia. 
1992;33:1123– 31.
 8. Auriel E, Landov H, Blatt I, Theitler J, Gandelman- Marton R, 
Chistik V, et al. Quality of life in seizure- free patients with epi-
lepsy on monotherapy. Epilepsy Behav. 2009;14:130– 3.
 9. Carpay JA, Aldenkamp AP, van Donselaar CA. Complaints associ-
ated with the use of antiepileptic drugs: results from a community- 
based study. Seizure. 2005;14:198– 206.
2170 |   CONTENTO ET al.
 10. Krauss GL, Gondek S, Krumholz A, Paul S, Shen F. “The Scarlet 
E”: The presentation of epilepsy in the English language print 
media. Neurology. 2000;54:1894– 8.
 11. Siqueira NF, Guerreiro MM, de Souza EAP. Self- esteem, social 
support perception and seizure controllability perception in ado-
lescents with epilepsy. Arq Neuropsiquiatr. 2011;69:770– 4.
 12. Schmidt D, Löscher W. Uncontrolled epilepsy following discon-
tinuation of antiepileptic drugs in seizure- free patients: a review of 
current clinical experience. Acta Neurol Scand. 2005;111:291– 300.
 13. Lamberink HJ, Otte WM, Geleijns K, Braun KPJ. Antiepileptic 
drug withdrawal in medically and surgically treated patients: a 
meta- analysis of seizure recurrence and systematic review of its 
predictors. Epileptic Disord. 2015;17:211– 28.
 14. Chadwick DW. Randomized study of antiepileptic drug withdrawal 
in patients in remission. Medical Research Council Antiepileptic 
Drug Withdrawal Study Group. Lancet. 1991;337:1175– 80.
 15. Lossius MI, Hessen E, Mowinckel P, Stavem K, Erikssen J, 
Gulbrandsen P, et al. Consequences of antiepileptic drug with-
drawal: a randomized, double- blind study (Akershus Study). 
Epilepsia. 2008;49:455– 63.
 16. Dooley J, Gordon K, Camfield P, Camfield C, Smith E. 
Discontinuation of anticonvulsant therapy in children free of sei-
zures for 1 year: a prospective study. Neurology. 1996;46:969– 74.
 17. Braathen G, Melander H. Early discontinuation of treatment in 
children with uncomplicated epilepsy: a prospective study with a 
model for prediction of outcome. Epilepsia. 1997;38:561– 9.
 18. Geerts AT, Niermeijer JMF, Peters ACB, Arts WFM, Brouwer OF, 
Stroink H, et al. Four- year outcome after early withdrawal of antie-
pileptic drugs in childhood epilepsy. Neurology. 2005;64:2136– 8.
 19. Prognostic index for recurrence of seizures after remission of ep-
ilepsy. Medical Research Council Antiepileptic Drug Withdrawal 
Study Group. Br Med J. 1993;306:1374– 8.
 20. Lin J, Ding S, Li X, Hua Y, Wang X, He R, et al. External valida-
tion and comparison of two prediction models for seizure recur-
rence after the withdrawal of antiepileptic drugs in adult patients. 
Epilepsia. 2020;61:115– 24.
 21. Chu S- S, Tan G, Wang X- P, Liu L. Validation of the predictive 
model for seizure recurrence after withdrawal of antiepileptic 
drugs. Epilepsy Behav. 2021;114:106987.
 22. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross H, 
Elger EC, et al. ILAE official report: a practical clinical definition 
of epilepsy. Epilepsia. 2014;55:475– 82.
 23. Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, 
Sander JW, et al. Recommendation for a definition of acute symp-
tomatic seizure. Epilepsia. 2010;51:671– 5.
 24. Wang X, He R, Zheng R, Ding S, Wang Y, Li X, et al. Relative 
seizure relapse risks associated with antiepileptic drug with-
drawal after different seizure- free periods in adults with focal 
epilepsy: a prospective, controlled follow- up study. CNS Drugs. 
2019;33:1121– 32.
 25. Tennison M, Greenwood R, Lewis D, Thorn M. Discontinuing 
antiepileptic drugs in children with epilepsy. A comparison 
of a six- week and a nine- month taper period. N Engl J Med. 
1994;330:1407– 10.
 26. Serra JG, Montenegro MA, Guerreiro MM. Antiepileptic drug 
withdrawal in childhood: does the duration of tapering off matter 
for seizure recurrence? J Child Neurol. 2005;20:624– 6.
 27. Specchio LM, Tramacere L, La Neve A, Beghi E. Discontinuing 
antiepileptic drugs in patients who are seizure free on monother-
apy. J Neurol Neurosurg Psychiatry. 2002;72:22– 5.
 28. Shinnar S, Berg AT, Moshé SL, Kang H, O’Dell C, Alemany M, 
et al. Discontinuing antiepileptic drugs in children with epilepsy: a 
prospective study. Ann Neurol. 1994;35:534– 45.
 29. Chadwick D, Taylor J, Johnson T. Outcomes after seizure recur-
rence in people with well- controlled epilepsy and the factors that 
influence it. The MRC Antiepileptic Drug Withdrawal Group. 
Epilepsia. 1996;37:1043– 50.
 30. Bouma PAD, Peters ACB, Brouwer OF. Long term course of 
childhood epilepsy following relapse after antiepileptic drug with-
drawal. J Neurol Neurosurg Psychiatry. 2002;72:507– 10.
 31. Li Y, Chen S, Qin J, She Y, Chen Y, Liu X, et al. Risk of seizure 
recurrence from antiepileptic drug withdrawal among seizure- free 
patients for more than two years. Epilepsy Behav. 2020;113:107485.
 32. Schmidt D, Sillanpää M. Stopping epilepsy treatment in seizure 
remission: Good or bad or both? Seizure. 2017;44:157– 61.
 33. Schmidt D. AED discontinuation may be dangerous for seizure- 
free patients. J Neural Transm. 2011;118:183– 6.
 34. Del Felice A, Beghi E, Boero G, La Neve A, Bogliun G, De Palo 
A, et al. Early versus late remission in a cohort of patients with 
newly diagnosed epilepsy. Epilepsia. 2010;51(1):37– 42.
 35. Somerville ER. Aggravation of partial seizures by antiepilep-
tic drugs: Is there evidence from clinical trials? Neurology. 
2002;59:79– 83.
 36. Boran E, Sarnthein J, Krayenbühl N, Ramantani G, Fedele T. 
High- frequency oscillations in scalp EEG mirror seizure frequency 
in pediatric focal epilepsy. Sci Rep. 2019;9:16560.
 37. Van Klink NEC, Van’t Klooster MA, Leijten FSS, Jacobs J, Braun 
KPJ, Zijlmans M. Ripples on rolandic spikes: a marker of epilepsy 
severity. Epilepsia. 2016;57:1179– 89.
 38. Qian P, Li H, Xue J, Yang Z. Scalp- recorded high- frequency os-
cillations in atypical benign partial epilepsy. Clin Neurophysiol. 
2016;127:3306– 13.
 39. Gong P, Xue J, Qian P, Yang H, Liu X, Cai L, et al. Scalp- recorded 
high- frequency oscillations in childhood epileptic encephalopathy 
with continuous spike- and- wave during sleep with different etiolo-
gies. Brain Dev. 2018;40:299– 310.
 40. Sen OC, Yang RC, Wu RC, Chiang CT, Lin LC. Determination 
of antiepileptic drugs withdrawal through EEG hjorth parameter 
analysis. Int J Neural Syst. 2020;30:2050036.
How to cite this article: Contento M, Bertaccini B, 
Biggi M, Magliani M, Failli Y, Rosati E, et al. 
Prediction of seizure recurrence risk following 
discontinuation of antiepileptic drugs. Epilepsia. 
2021;62:2159– 2170. https://doi.org/10.1111/epi.16993
